ArticleCancer research2022

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.

Weijia Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.